This study confirmed that patients diagnosed with invasive breast cancer aged 18–40 years have a high breast-cancer-specific mortality, and a high proportion are BRCA1 and BRCA2 mutation carriers. This evidence concerns the gene BRCA2 and breast carcinoma.